Akebia Therapeutics, Inc. (AKBA) key performance indicators and operating metrics (5 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| License, Collaboration and Other Revenues | 1.6M | FY2026-Q1 |
| Vafseo Net Product Revenues Guidance | 15.8M | FY2026-Q1 |
| Auryxia Net Product Revenues | 36.2M | FY2026-Q1 |
| U.S. Dialysis Patient Coverage Under Dialysis Provider Contracts for Vafseo (Share) | 100.00 percent | FY2025-Q2 |
| Vafseo Prescribers Writing Prescriptions | 725.00 | FY2025-Q2 |
Back to AKBA overview · AKBA earnings · AKBA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.